PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

New hope in the fight against unmet diseases

15-Dec-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, announced a strategic research partnership aimed at advancing modern phenotypic drug ...

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost to deploy its SITESEEKER Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets

03-Nov-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will ...

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

07-Sep-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-project target discovery collaboration with Roche. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for ...

The two startups NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics

19-Jan-2022 - NeoCura Bio-Medical Technology Co., Ltd., a RNA-based drug research and development company in China, and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, announced an oncology drug discovery research collaboration As part of the collaboration, ...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Start-ups combine biotechnology and artificial intelligence

06-Jan-2022 - PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, announced a collaborationto study oncology targets currently considered ...

PhoreMost closes £33M Series B financing

Start-up is advancing its pipeline of novel therapies for oncology and diseases of ageing

25-Mar-2021 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors ...

PhoreMost completes $15M Series-A round to enter drug discovery

Investment to fund expansion of operations and progression of drug target pipeline

22-May-2018 - PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug ...

PhoreMost and Plexxikon collaborate to identify novel drug targets

16-Apr-2018 - PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo. Under the agreement, PhoreMost will apply its ...

PhoreMost Ltd and University of Cambridge collaborate

Identifying innovative drug targets for neurodegenerative disease

14-Oct-2016 - PhoreMost Ltd (PhoreMost), a biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. The groups will study and translate essential cellular ...

PhoreMost Awarded £1.4M Innovate UK Funding to Develop Lead Oncology Programme

13-May-2015 - PhoreMost Ltd announced that it has been selected to receive a funding award of £1.4M (approximately $2.14M USD) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers.Based on PhoreMost’s proprietary Protein Interference technology, the ...